Recent advances in c-Met-based dual inhibitors in the treatment of cancers
Article in European Journal of Medicinal Chemistry (May 2024)
The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.
4‐{3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐b][1,2,4]triazin‐6‐yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator
Article in Archiv der Pharmazie (March 2024)
Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters
Article in Toxicology and Applied Pharmacology (February 2024)